Real-World Experience with Lifitegrast Ophthalmic Solution (Xiidra^®) in the US and Canada: Retrospective Study of Patient Characteristics, Treatment Patterns, and Clinical Effectiveness in 600 Patients with Dry Eye Disease

John A Hovanesian1 Harvard Eye Associates, Laguna Hills, CA, USA;2 UCLA Jules Stein Eye Institute, Los Angeles, CA, USA

Kelly K Nichols3 School of Optometry, University of Alabama at Birmingham, Birmingham, AL, USA

Mitchell Jackson4 Jacksoneye, Lake Villa, IL, USA

James Katz5 The Midwest Center for Sight, Des Plaines, IL, USA

Arthur Chan6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Mrudula B Glassberg6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Brigitte Sloesen7 Novartis Pharma AG, Basel, Switzerland

Caroline Korves8 Analysis Group, Inc., Boston, MA, USA

Catherine Nguyen9 Analysis Group, Inc., Los Angeles, CA, USA

Annie Syntosi7 Novartis Pharma AG, Basel, SwitzerlandCorrespondence[email protected]

Your download is now in progress and you may close this window